Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

MUSKBTC

(MUSKBTC)

Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
07/01/20241:45AMGlobeNewswire Inc.Wendel joins Providence to support Globeducate, a leading international K-12 education group, through its next phase of growthEU:MFWendel SA
07/01/20241:45AMGlobeNewswire Inc.Wendel et Providence accompagneront conjointement Globeducate, un groupe d’écoles internationales de la maternelle au secondaire, dans sa prochaine phase de croissanceTG:WISWendel SA
07/01/20241:45AMGlobeNewswire Inc.Sword Group: Acquisitions in the UKTG:9RSSword Group
07/01/20241:45AMGlobeNewswire Inc.Sword Group: Acquisitions in the UKEU:SWPSword Group
07/01/20241:45AMGlobeNewswire Inc.Sword Group : Acquisitions en Grande-BretagneEU:SWPSword Group
07/01/20241:45AMGlobeNewswire Inc.Sword Group : Acquisitions en Grande-BretagneLSE:0MN5Sword Group Se
07/01/20241:45AMGlobeNewswire Inc.Sword Group : Acquisitions en Grande-BretagneTG:9RSSword Group
07/01/20241:45AMGlobeNewswire Inc.Sword Group: Acquisitions in the UKLSE:0MN5Sword Group Se
07/01/20241:38AMAlliance NewsAlliance NewsIrish slowdown in manufacturing accelerates in June; outlook positive
07/01/20241:33AMPR Newswire (US)Global Times: CPC members reach 99.185 million
07/01/20241:31AMGlobeNewswire Inc.Kalmar’s financial information in 2024
07/01/20241:30AMAlliance NewsAlliance NewsGET READY: Induction Healthcare Group, Porvair at 0700 BSTLSE:INHCInduction Healthcare Group Plc
07/01/20241:30AMAlliance NewsAlliance NewsGET READY: Induction Healthcare Group, Porvair at 0700 BSTLSE:PRVPorvair Plc
07/01/20241:30AMAlliance NewsAlliance NewsAlliance News UK - start of day
07/01/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’EU:OSEOSE Immunotherapeutics
07/01/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ LSE:0RADOse Immunotherapeutics Sa
07/01/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’EU:OSEOSE Immunotherapeutics
07/01/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’LSE:0RADOse Immunotherapeutics Sa
07/01/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’TG:6OPOSE Immunotherapeutics
07/01/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ EU:OSEOSE Immunotherapeutics
07/01/20241:30AMGlobeNewswire Inc.OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’ TG:6OPOSE Immunotherapeutics
07/01/20241:30AMGlobeNewswire Inc.BGHL (GBP): NAV(s)LSE:BGHSBoussard & Gavaudan Holding Limited
07/01/20241:30AMGlobeNewswire Inc.BGHL (EUR): NAV(s)EU:BGHLBoussard And Gavaudan Holding Limited
07/01/20241:30AMGlobeNewswire Inc.Multitude SE: Repurchase of own shares 28.06.2024TG:FRUMultitude SE
07/01/20241:30AMGlobeNewswire Inc.Kalmar specifies its outlook for 2024
07/01/20241:30AMGlobeNewswire Inc.Sampo plc’s share buybacks 28 June 2024
07/01/20241:30AMGlobeNewswire Inc.BGHL (EUR): NAV(s)LSE:BGHLBoussard & Gavaudan Holding Limited
07/01/20241:30AMGlobeNewswire Inc.Multitude SE: Repurchase of own shares 28.06.2024XE:FRUMultitude SE
07/01/20241:30AMGlobeNewswire Inc.BGHL (GBP): NAV(s)EU:BGHSBoussard and Gavaudan Holding
07/01/20241:30AMGlobeNewswire Inc.Atlas Luxco S.à r.l., a subsidiary of Atlas Investissement S.A.S., announces public offers to purchase all of the outstanding common shares and SDRs of Millicom International Cellular S.A. for USD 24.00 in cash per Common Share and per SDR

Your Recent History

Delayed Upgrade Clock